Difference between revisions of "Nedaplatin (Aqupla)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m
Line 7: Line 7:
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
*[[Nasopharyngeal carcinoma]]
 
*[[Nasopharyngeal carcinoma]]
 +
*[[Non-small cell lung cancer]]
 
==Also known as==
 
==Also known as==
 
*'''Code name:''' 254-S
 
*'''Code name:''' 254-S
Line 21: Line 22:
  
 
[[Category:Nasopharyngeal carcinoma medications]]
 
[[Category:Nasopharyngeal carcinoma medications]]
 +
[[Category:Non-small cell lung cancer medications]]
 
[[Category:PMDA approved drugs]]
 
[[Category:PMDA approved drugs]]

Revision as of 12:47, 24 April 2019

General information

Class/mechanism: A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. [1]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

Also known as

  • Code name: 254-S
  • Generic name: nedaplat
  • Brand name: Aqupla

References